Sudden cardiac death in young competitive athletes due to genetic cardiac abnormalities

Anadolu Kardiyoloji Dergisi

Volumn 9, Issue SUPPL. 2, 2009, Pages 17-23

  Wever Pinzon, Omar E ^a   Myerson, Merle ^a   Sherrid, Mark V ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Arrhythmogenic ventricular cardiomyopathy; Athlete; Hypertrophic cardiomyopathy; Ion channelopathies; Sudden cardiac death

Indexed keywords

ATHLETE; BRUGADA SYNDROME; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CLINICAL FEATURE; EUROPE; GENETIC DISORDER; HEART DISEASE; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LONG QT SYNDROME; REVIEW; SUDDEN DEATH; UNITED STATES;

ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; ATHLETES; BRUGADA SYNDROME; CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; HEART DEFECTS, CONGENITAL; HUMANS; LONG QT SYNDROME; TACHYCARDIA, VENTRICULAR;

EID: 76149141626     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Maron BJ, Gohman TE, Aeppli D. Prevalence of Sudden Cardiac Death During Competitive Sports Activities in Minnesota High School Athletes. J Am Coll Cardiol 1998; 32: 1881-4.
2. Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G. Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol 2003; 42: 1959-63.
3. Maron BJ. Hypertrophic cardiomyopathy and other causes of sudden cardiac death in young competitive athletes, with considerations for preparticipation screening and criteria for disqualification. Cardiol Clin 2007; 25: 399-414.
4. Maron BJ, Thompson PD, Ackerman MJ, Balady G, Berger S, Cohen D, et al. Recommendations and Considerations Related to Preparticipation Screening for Cardiovscular Abnormalities in Coompetitive Athletes: 2007 Update. A Scientific Statement From the American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Circulation 2007; 115: 1643-55.
5. Corrado D, Pellica A, Bjornstad HH, Vanhees L, Biffi A, Borjesson M, et al. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005; 26: 516-24.
6. Maron BJ, Gardin JM, Flack JM, Vanhees L, Biffi A, Borjesson M, et al. Assessment of the prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study. Circulation 1995; 92: 785-9.
7. Maron BJ, Carney KP, Lever HM, Lewis JF, Barac I, Casey SA, et al. Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 41: 974-80.
8. Maron BJ. Hypertrophic Cardiomyopathy: A systematic review. JAMA 2002; 287; 1308-20.
9. Maron BJ, Mathenge R, Casey S, Poliac LC, Longe TF. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol 1999; 33: 1590-5.
10. Pelliccia A, Fagard R, Bjornstad H, Anastassakis A, Arbustini E, Assanelli D, et al. ESC Report: Recommendations for competitive sports participation in athletes with cardiovascular disease. A consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005; 26: 1422-45.
11. Pelliccia A, Corrado D, Bjornstad H, Panhuyzen-Goedkoop N, Urhausen A, Carre F, et al. Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis. Eur J Cardiovasc Prev Rehabil 2006; 13: 876-85.
12. Maron BJ, Ackerman MJ, Nishimura RA, Pyeritz RE, Towbin JA, Udelson JE. 36th Bethesda Conference. Task Force 4: HCM and Other Cardiomyopathies, Mitral Valve Prolapse, Myocarditis, and Marfan Syndrome. J Am Coll Cardiol 2005; 45: 1340-5.
13. Lindstrom L, Nylander E, Larsson H, Wranne B. Left ventricular involvement in Arrhythmogenic right ventricular cardiomyopathya scintigraphic and echocardiographic study. Clin Physiol Funct Imaging 2005; 25: 171-7.
14. Thiene G, Basso C. Arrhythmogenic right ventricular cardiomyopathy: an update. Cardiovasc Pathol 2001; 10: 109-17.
15. Kies P, Bootsma M, Bax J, Schalij MJ, van der Wall EE. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: screening, diagnosis, and treatment. Heart Rhythm 2006; 3: 225-34.
16. McKenna WJ, Thiene G, Nava A, Fontaliran F, Blomstrom-Lundqvist C, Fontaine G, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy: task force of the working group myocardial and pericardial disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br Heart J 1994; 71: 215-28.
17. Alizad A, Seward JB. Echocardiographic features of genetic diseases. : Part 1: cardiomyopathy. J Am Soc Echocardiogr 2000; 13: 73-86.
18. Yoerger DM, Marcus F, Sherrill D, Calkins H, Towbin JA, Zareba W, et al. Echocardiographic findings in patients meeting task force criteria for arrhythmogenic right ventricular dysplasia: New insights from the multidisciplinary study of right ventricular dysplasia. J Am Coll Cardiol 2005; 45: 860-5.
19. Marcus FI, Fontaine G. Arrhythmogenic right ventricular dysplasia/ cardiomyopathy: a review. Pacing Clin Electrophysiol 1995; 18: 1298-314.
20. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J 1957; 54: 59-68.
21. Goldenberg I, Moss AJ. Long QT Syndrome. J Am Coll Cardiol 2008; 5: 2291-300.
22. Maron BJ. Sudden death in young athletes. N Engl J Med 2003; 349: 1064-75.
23. Basavarajaiah S, Wilson M, Whyte G, Shah A, Behr E, Sharma S. et al. Prevalence and significance of an isolated long QT interval I elite athletes. Eur Heart J 2007; 28: 2944-9.
24. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome: an update. Circulation 1993; 88: 782-4.
25. Zipes DP, Ackerman MJ, Estes NA 3rd, Grant AO, Myerburg RJ, Van Hare G. Task Force 7: Arrhythmias. J Am Coll Cardiol 2005; 45: 1354-63.
26. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation, and sudden cardiac death: a distinct clinical and electrocardiographic syndrome: a multicenter report. J Am Coll Cardiol 1992; 20: 1391-6.
27. Nagase S, Kusano KF, Morita H, Nishii N, Banba K, Watanabe A, et al. Longer repolarization in the epicardium at the right ventricular outflow tract causes type 1 electrocardiogram in patients with Brugada syndrome. J Am Coll Cardiol 2008; 51: 1154-61.
28. Eckardt L. Gender differences in Brugada syndrome. J Cardiovasc Electrophysiol 2007; 18: 422-4.
29. Wilde AA, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P, et al. Proposed diagnostic criteria for the Brugada syndrome. Eur Heart J 2002; 23: 1648-54.
30. Swan H, Piippo K, Viitasalo M, Heikkilä P, Paavonen T, Kainulainen K, et al. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J Am Coll Cardiol 1999; 34: 2035-42.
31. Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 2001; 69: 1378-84.
32. Nam G-B, Burashnikov B, Antzelevitch C. Cellular mechanisms underlying the development of catecholaminergic ventricular tachycardia. Circulation 2005; 111: 2727-33.
33. Sumitomo N, Harada K, Nagashima M, Yasuda T, Nakamura Y, Aragaki Y, et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart 2003; 89: 66-70.